Addex Therapeutics Ltd.

ADXN · NASDAQ

Addex has real allosteric-modulator science, but the public-company story now turns on CHF 1.6 million of year-end cash, a delayed 2025 Form 20-F, chronic-cough preclinical data, dipraglurant repositioning, and a 20% Neurosterix option.

Follow Add to Watchlist Ask Question

NASDAQ ADXN Coverage Bootstrap Biotechnology Clinical-stage Biotech Allosteric Modulators

Latest ReportMay 14, 2026Addex: The Tiny Biotech Racing Its Cash Clock With a Cough Drug and a Spin-Out OptionView report ->Total Reports1Published reportView all ->Active Discussions0No visible comments yetView discussions ->Member WorkspaceLockedFinancials, timeline, comparisons, scorecard, and discussion require a paid login.View access ->

Admin-only preview

Valuation is limited to admins for now.

The valuation workbench is hidden from non-admin users until market-data licensing and trust disclosures are production-ready.